Neurotrophic tyrosine receptor kinase (NTRK) inhibitors represent the latest advancement as a treatment option in targeted therapies for malignant disease. NTRK gene fusions involving NTRK1, 2 or 3 are implicated as genetics drivers for a number of tumour types which arise within adult and paedatric patients. NTRK inhibitors (Larotrectinib and Entrectinib) are effective agents which have demonstrated clinical benefit in the treatment of NTRK fusion positive solid tumours. Larotrectinib represents the first targeted agent to receive approval from international authorisation and commissioning bodies for the treatment of a specific genetic expression indiscriminate of the site from which the tumour has arisen. As such NTRK inhibitors could pave the way for international healthcare bodies to adopt a similar approach for future targeted therapies thereby altering the manner in which healthcare providers and patients are able to access and utilise innovative, targeted treatment options in future. The potential implications of this new approach are likely to impact upon several aspects of the traditional authorisation and commissioning pathways with potential changes to the design of clinical trials, the review and approval process by regulatory bodies and immunohistopathology services.
DrilonALaetschTWKummarS, et al.
Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med2018;
378: 731–739.
3.
ChalmersZRConnellyCFFabrizioD, et al.
Analysis of 100,000 human cancer genomes reveals the landscape of tumour mutational burden. Genome Med2017;
9: 34.
4.
VillanuevaALlovetJM.Targeted therapies for hepatocellular carcinoma. Gastroenterology2011;
140: 1410–1426.
5.
HirschFRScagliottiGVMulshineJL, et al.
Lung cancer: current therapies and new targeted treatments. Lancet2017;
389: 299–311.
6.
KatoSOkamuraRSicklickJK, et al.
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer2020;
146: 3450–3460.
7.
HymanDMPuzanovISubbiahV, et al.
Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med2015;
373: 726–736.
8.
AmatuASartore-BianchiASienaS, et al.
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open2016;
1: e000023.
9.
Martin-ZancaDHughesSHBarbacidM, et al.
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature1986;
319: 743–748.
10.
KnezevichSRMcFaddenDETaoW, et al.
A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet1998;
18: 184–187.
11.
TognonCKnezevichSRHuntsmanD, et al.
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell2002;
2: 367–376.
12.
BourgeoisJMKnezevichSRMathersJA, et al.
Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol2000;
24: 937–946.
13.
VaishnaviACapellettiMLeAT, et al.
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med2013;
19: 1469–1472.
14.
VaishnaviALeATDoebeleRC, et al.
TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov2015;
5: 25–34.
15.
DrilonASienaSOuS-HI, et al.
Safety and antitumor activity of the multitargeted pan-Trk, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov2017;
7: 400–409.
16.
CardonaAFArrietaORuiz-PatiñoA, et al.
Precision medicine and its implementation in patients with NTRK fusion genes perspective from developing countries. Ther Adv Respir Dis2020;
14: 1753466620938553.
National institute for health and care excellence. Technology appraisal guidance (TA630) Larotrectinib for treating NTRK fusion-positive solid tumours, www.nice.org.uk/guidance/ta630 (27 May 2020, accessed 3 September 2020).
20.
NaitoYMishimaSAkagiK, et al.
Japan Society of Clinical Oncology/Japanese Society of Medical Oncology-led Clinical Recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology. Int J Clin Oncol2020;
25: 403–417.
21.
Penault-LlorcaFRudzinskiERSepulvedaAR, et al.
Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol2019;
72: 460–467.
22.
ElkinEBWeinsteinMCWinerEP, et al.
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol2004;
22: 854–863.
23.
ParkJJHSidenEZorattiMJ, et al.
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials2019;
20: 572.
24.
HirakawaAAsanoJSatoH, et al.
Master protocol trials in oncology: review and new trial designs. Contemp Clin Trials Commun2018;
12: 1–8.
25.
CoccoEScaltritiMDrilonA, et al.
NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol2018;
15: 731–747.
26.
GrovesE.Oncology workforce skills and competencies required for molecular medicine. Eur J Hosp Pharm2019;
27: 249–250.
27.
DietelMJöhrensKLaffertM, et al.
Predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther2013;
20: 211–221.
